Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 4/20 | 0.60 |
| ▸ | TP53 | P04637 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 6/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.58 |
| ▸ | POLB | P06746 | 2/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 5/20 | 0.55 |
| ▸ | HTT | P42858 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29991362 | 1.00 | GAA (0.60) | GAATP53KMT2ANPSR1MAPT | |
| SCHEMBL2589170 | 0.88 | ALDH1A1 (0.63) | GAAKMT2ANPSR1MAPTALDH1A1 | |
| SCHEMBL28467109 | 0.88 | GAA (0.47) | GAATP53KMT2ANPSR1MAPT | |
| SCHEMBL28158035 | 0.88 | GAA (0.47) | GAATP53KMT2ANPSR1MAPT | |
| SCHEMBL11660471 | 0.85 | MAPT (0.70) | GAATP53KMT2ANPSR1MAPT | |
| SCHEMBL28020299 | 0.85 | GAA (0.57) | GAATP53KMT2ANPSR1MAPT | |
| SCHEMBL17662315 | 0.85 | KMT2A (0.60) | GAATP53KMT2ANPSR1MAPT | |
| SCHEMBL4568017 | 0.85 | GAA (0.50) | GAAKMT2ANPSR1MAPTPOLB | |
| SCHEMBL24732039 | 0.84 | F10 (0.50) | GAATP53KMT2ANPSR1MAPT | |
| SCHEMBL14598625 | 0.84 | TDP1 (0.51) | KMT2AMAPTALDH1A1POLBMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2411376-B1 | INHIBITORS OF NF-KB | PROFECTUS BIOSCIENCES INC (US) | 2015-04-22 | — | — | EP | disclosed |
| US-8629164-B2 | Inhibitors of NF-κB | PROFECTUS BIOSCIENCES, INC. (US) | 2014-01-14 | — | — | US | disclosed |
| US-8629164-B2 | Inhibitors of NF-κB | PROFECTUS BIOSCIENCES, INC. (US) | 2014-01-14 | — | — | US | disclosed |
| US-8629164-B2 | Inhibitors of NF-κB | PROFECTUS BIOSCIENCES, INC. (US) | 2014-01-14 | — | — | US | disclosed |
| CN-102439000-A | Benzamide and naphthamide derivatives inhibiting nuclear factor- kap pa (b) - (nf-kb) | PROFECTUS BIOSCIENCES INC (US) | 2012-05-02 | — | — | CN | disclosed |
| CN-102414190-A | Inhibitors of NF-kB | PROFECTUS BIOSCIENCES INC | 2012-04-11 | — | — | CN | disclosed |
| EP-2424850-A1 | BENZAMIDE AND NAPHTHAMIDE DERIVATIVES INHIBITING NUCLEAR FACTOR- KAP PA (B) - (NF-KB) | Profectus Biosciences, Inc. (US) | 2012-03-07 | — | — | EP | disclosed |
| US-20120046357-A1 | Benzamide and Napthamide Derivatives Inhibiting Nuclear Factor-Kappa (B) - (NK-kB) | PROFECTUS BIOSCIENCES, INC. (US) | 2012-02-23 | — | — | US | disclosed |
| US-20120046357-A1 | Benzamide and Napthamide Derivatives Inhibiting Nuclear Factor-Kappa (B) - (NK-kB) | PROFECTUS BIOSCIENCES, INC. (US) | 2012-02-23 | — | — | US | disclosed |
| EP-2411376-A1 | INHIBITORS OF NF-KB | Profectus Biosciences, Inc. (US) | 2012-02-01 | — | — | EP | disclosed |
| US-20120015952-A1 | Inhibitors of NF-KB | PROFECTUS BIOSCIENCES, INC. (US) | 2012-01-19 | — | — | US | disclosed |
| US-20120015952-A1 | Inhibitors of NF-KB | PROFECTUS BIOSCIENCES, INC. (US) | 2012-01-19 | — | — | US | disclosed |
| WO-2010127058-A1 | BENZAMIDE AND NAPHTHAMIDE DERIVATIVES INHIBITING NUCLEAR FACTOR- KAP PA (B) - (NF-KB) | PROFECTUS BIOSCIENCES, INC. (US) | 2010-11-04 | — | — | WO | disclosed |
| WO-2010111460-A1 | INHIBITORS OF NF-KB | PROFECTUS BIOSCIENCES, INC. (US) | 2010-09-30 | — | — | WO | disclosed |
| WO-2010111460-A1 | INHIBITORS OF NF-KB | PROFECTUS BIOSCIENCES, INC. (US) | 2010-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015952-A1 | Inhibitors of NF-KB | NFKBIA, IKBKB, IKBKG | GAA 1468/4885TP53 980/4885KMT2A 2968/4885 |
| US-20120046357-A1 | Benzamide and Napthamide Derivatives Inhibiting Nuclear Factor-Kappa (B) - (NK-kB) | NFKBIA, IKBKB, NFKB1 | GAA 989/4885TP53 2427/4885KMT2A 468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.